Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02308293
Other study ID # End_lac_sympt
Secondary ID
Status Completed
Phase N/A
First received November 14, 2014
Last updated November 23, 2016
Start date January 2015
Est. completion date July 2016

Study information

Verified date April 2016
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Iatrogenic hypoglycemia is the most frequent acute complication of insulin therapy in people with type 1 diabetes (T1DM). Recurrent hypoglycemic events initiate a process of habituation, characterized by suppression of hypoglycemic symptoms, eventually leading to hypoglycemia unawareness, which creates a particularly high risk of severe hypoglycemia. Recent evidence suggest a pivotal role for (brain) lactate in the pathogenesis of hypoglycemia unawareness. Indeed, exogenous lactate administration may preserve brain function and attenuate counterregulatory responses to and symptomatic awareness of hypoglycemia. It is unknown whether endogenous elevation of plasma lactate produces the same effects and whether such effects differ between patients with T1DM with and without hypoglycemia unawareness and healthy controls.

Objective: To investigate the effect of elevated levels of endogenous lactate on brain lactate accumulation and on counterregulatory responses to, symptomatic awareness of and cognitive function during hypoglycemia in patients with T1DM with and without hypoglycemia unawareness and normal controls.

Hypothesis: The investigators hypothesize first that endogenous lactate, when raised through high intensity exercise, preserves neuronal metabolism during subsequent hypoglycemia, which in turn will attenuate counterregulatory hormone responses, appearance of symptoms and deterioration of cognitive function. Second, the investigators posit that these effects will be augmented in patients with hypoglycemia unawareness compared to healthy subjects and T1DM patients with normal awareness as a consequence of greater transport capacity of lactate into the brain.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2016
Est. primary completion date May 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion criteria for healthy subjects

- Age: 18-40 years

- Body-Mass Index: 18-30 kg/m2

- Blood pressure: <160/90 mmHg

- Recreationally active: i.e. taking part in competitive sport or regular exercise training, of a non-professional nature, once or more a week.

Inclusion criteria T1DM patients with normal hypoglycemic awareness

- Diabetes duration = 1 year

- Age: 18-40 years

- Body-Mass Index: 18-30 kg/m2

- HbA1c: 42-75 mmol/mol (6-9%)

- Outcome Clarke questionnaire: 0-1

- Blood pressure: <160/90 mmHg

- Recreationally active: i.e. taking part in competitive sport or regular exercise training, of a non-professional nature, once or more a week

Inclusion criteria T1DM patients with hypoglycemia unawareness

- Diabetes duration = 1 year

- Age: 18-40 years

- Body-Mass Index: 18-30 kg/m2

- HbA1c: 42-75 mmol/mol (6-9%)

- Outcome Clarke questionnaire: =>3

- Blood pressure: <160/90 mmHg

- Recreationally active

Exclusion criteria:

- Inability to provide informed consent

- Presence of any medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders

- Use of any medication, except for oral contraceptives

- MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)

- Orthopedic and/or neurological diseases that impair exercise

- Cardiopulmonary disease as stated in the 2001 American heart association and 2002 American college of cardiology/American heart association guidelines

Additional exclusion criteria for all T1DM patients:

- Use of any other medication than insulin, except for oral contraceptives or stable thyroxine supplementation therapy

- complications of T1DM, including proliferative retinopathy, neuropathy or nephropathy

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Intervention

Behavioral:
High intensity exercise
3x30 seconds 'all out' sprints
Lay down comfortably
rest

Locations

Country Name City State
Netherlands Radboud umc Nijmegen

Sponsors (3)

Lead Sponsor Collaborator
Radboud University Dutch Diabetes Research Foundation, European Foundation for the Study of Diabetes

Country where clinical trial is conducted

Netherlands, 

References & Publications (5)

De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes. 2013 Sep;62(9):3075-80. doi: 10.2337/db13-0313. — View Citation

Maddock RJ, Casazza GA, Buonocore MH, Tanase C. Vigorous exercise increases brain lactate and Glx (glutamate+glutamine): a dynamic 1H-MRS study. Neuroimage. 2011 Aug 15;57(4):1324-30. doi: 10.1016/j.neuroimage.2011.05.048. — View Citation

van de Ven KC, de Galan BE, van der Graaf M, Shestov AA, Henry PG, Tack CJ, Heerschap A. Effect of acute hypoglycemia on human cerebral glucose metabolism measured by ¹³C magnetic resonance spectroscopy. Diabetes. 2011 May;60(5):1467-73. doi: 10.2337/db10-1592. — View Citation

van de Ven KC, van der Graaf M, Tack CJ, Heerschap A, de Galan BE. Steady-state brain glucose concentrations during hypoglycemia in healthy humans and patients with type 1 diabetes. Diabetes. 2012 Aug;61(8):1974-7. doi: 10.2337/db11-1778. — View Citation

van de Ven KC, van der Graaf M, Tack CJ, Klomp DW, Heerschap A, de Galan BE. Optimized [1-(13)C]glucose infusion protocol for 13C magnetic resonance spectroscopy at 3T of human brain glucose metabolism under euglycemic and hypoglycemic conditions. J Neurosci Methods. 2010 Jan 30;186(1):68-71. doi: 10.1016/j.jneumeth.2009.10.025. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Plasma glucose concentration Plasma glucose concentration, necessary to adjust glucose infusion rate During 60 min hypoglycemia No
Other Plasma insulin concentration (Insulin levels, measured in arterial plasma) Insulin levels, measured in arterial plasma During 60 min hypoglycemia No
Primary Plasma level of adrenaline in response to hypoglycemia (Adrenaline, measured in arterial plasma) during 60 m of hypoglycemia No
Secondary Plasma levels of other counter-regulatory hormones (Levels of counter-regulatory hormones measured in arterial plasma) Levels of counter-regulatory hormones measured in arterial plasma During 60 min hypoglycemia No
Secondary Glucose infusion rate (Amount of glucose 20% necessary to maintain plasma glucose at steady state values) Amount of glucose 20% necessary to maintain plasma glucose at steady state values During 60 min hypoglycemia No
Secondary Plasma lactate levels (Lactate levels measured in arterial plasma) Lactate levels measured in arterial plasma During 60 min hypoglycemia No
Secondary Cognitive functioning, as measured by cognitive tests Cognitive test will be: Dutch State Trait Anxiety Inventory, Digit Span, Stroop color word test, word fluency test, trail making test and Pasat During 60 min hypoglycemia No
Secondary Plasma levels of inflammatory markers (levels of cytokines) levels of cytokines During 60 min hypoglycemia No
Secondary Brain perfusion measured with ASL-MRI Brain perfusion measured with ASL-MRI During 60 min hypoglycemia No
Secondary Brain lactate accumulation measured with 1H-MRS Brain lactate levels measured with 1H-MRS During 60 min of hypoglycemia No
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1